✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Exit Type◇ research
Still_operating
Subsequent Funding◇ research
—
Received VC Funding◇ research
—
Current Employees◇ research
5
Peak Employees◇ research
—
Patents◇ research
2 filed
SBIR/STTR Awards◇ research
None
Filed Form D◇ research
Yes
Used Crowdfunding◇ research
No
Notes
Vivorté is best coded as active. Kentucky records show completed KAITC investments across 2015-2017, the company’s site and investor page remain live, and SEC materials show continued fundraising activity into 2021.
[Deep research 2026-04-11] 2024 research confirms continued active operations with fully functional website, active investor solicitation page, and commercial-stage products (Trabexus, Fortera, Regento). Current employee count: 5 per Gust profile. Company holds US patents 9,072,720 and 10,046,090 covering Trabexus technology. 2018 fundraising activity included $3M securities offering from Louisville address. Products are FDA-approved/cleared with ISO 13485:2016 facility certification. Leadership includes Ruth Voor (CEO, ex-J&J) and Dr. Voor (60+ publications). Sources: https://vivorte.com/, https://gust.com/companies/vivorte, https://orthospinenews.com/2017/10/03/vivorte-announces-the-commercial-availability-of-fortera-and-regento-bone-grafting-solutions-for-orthopedic-surgery/, https://www.bizjournals.com/louisville/news/2018/12/04/louisville-biotech-makes-bone-cement-and-wants-to.html
Last updated: Apr 11, 2026 · Evidence score: 5/5